Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…Over 48 months, GFR increased in the SGLT2i group (+13.5 ± 1.3) and declined in the insulin group (−4.2 ± 1.4; p < 0.01). …”

Supplementary file 4_Breast cancer burden in the United States (1990–2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.gif by Zhijian Huang (1649578)

“…Objective<p>Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years.…”

Data Sheet 4_Breast cancer burden in the United States (1990–2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.csv by Zhijian Huang (1649578)

“…Objective<p>Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years.…”

Supplementary file 1_Breast cancer burden in the United States (1990–2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.gif by Zhijian Huang (1649578)

“…Objective<p>Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years.…”

Supplementary file 2_Breast cancer burden in the United States (1990–2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.gif by Zhijian Huang (1649578)

“…Objective<p>Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years.…”

Supplementary file 3_Breast cancer burden in the United States (1990–2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.gif by Zhijian Huang (1649578)

“…Objective<p>Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years.…”

Data Sheet 3_Breast cancer burden in the United States (1990–2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.csv by Zhijian Huang (1649578)

“…Objective<p>Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years.…”

Data Sheet 1_Breast cancer burden in the United States (1990–2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.csv by Zhijian Huang (1649578)

“…Objective<p>Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years.…”

Data Sheet 2_Breast cancer burden in the United States (1990–2021) with a 15-year forecast: a comprehensive analysis based on the global burden of disease 2021.csv by Zhijian Huang (1649578)

“…Objective<p>Breast cancer (BC) is one of the most common cancers globally, placing a significant social burden. This study estimates the BC burden in the U.S. from 1990 to 2021 and projects future trends for the next 15 years.…”

Data Sheet 1_Longitudinal changes in bodyweight, body condition, and muscle condition in ageing pet cats: findings from the Cat Prospective Ageing and Welfare Study.docx by Christine R. Pye (22118977)

“…All three metrics showed significant non-linear associations with age. Bodyweight increased slightly from age 7 to 10 (estimated marginal mean 4.77–4.82 kg) before decreasing to 4.30 kg by age 16 years. …”

<b>Contrasting strategies, shared risk: 12-yr nitrogen addition compromises hydraulic safety in young and mature trees via distinct pathways</b> by Shijie Ning (17757825)

“…<p dir="ltr">Nitrogen (N) deposition is widely assumed to stimulate growth in N-limited temperate forests, yet how N deposition interacts with tree ontogeny to regulate the carbon–water processes that shape tree resilience, decline, and mortality under environmental stress remains unclear. …”